Bone mineral density change in type 1 Gaucher disease adults given velaglucerase alfa for 2 years

被引：1

作者：

Zimran, An ^{[1
,2
]}

Giraldo, Pilar ^{[3
,4
]}

Zahrieh, David ^{[5
]}

Crombez, Eric ^{[5
]}

Cohn, Gabriel ^{[5
]}

Elstein, Deborah ^{[1
,2
]}

机构：

[1] Shaare Zedek Med Ctr, Gaucher Clin, Jerusalem, Israel

[2] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel

[3] CIBERER, Zaragoza, Spain

[4] Hosp Univ Miguel Servet, Zaragoza, Spain

[5] Shire Human Genet Therapies Inc, Lexington, MA USA

来源：

MOLECULAR GENETICS AND METABOLISM | 2013年 / 108卷 / 02期

关键词：

D O I：

10.1016/j.ymgme.2012.11.279

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

265

引用

页码：S101 / S101

页数：1

共 50 条

[21] 482 Safety and Efficacy of Velaglucerase Alfa in Gaucher Disease Type 1 Patients Previously Treated with Imiglucerase [J].

G Grabowski ;

G Pastores ;

R Mardach ;

C Eng ;

L Smith ;

P Fernhoff ;

J Charrow ;

M Heisel-Kurth ;

N Longo ;

W Rhead ;

P Harmatz ;

A Mehta ;

P Giraldo ;

A Tylki-Szymanska ;

A Zimran ;

E Crombez .

Pediatric Research, 2010, 68 :246-247

[22] Bone density in Type 1 Gaucher disease [J].

Pastores, GM ;

Wallenstein, S ;

Desnick, RJ ;

Luckey, MM .

JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 (11) :1801-1807

[23] Markers of bone turnover in patients with type 1 Gaucher disease receiving long-term velaglucerase alfa enzyme replacement therapy [J].

Zimran, Ari ;

Mehta, Atul ;

Gonzalez, Derlis E. ;

Ben Dridi, Marie-Francoise ;

Lukina, Elena A. ;

Chang, Peter ;

Olivier, Clement ;

Elstein, Deborah .

MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) :S129-S130

[24] A Real-World Investigation of MRI Changes in Bone in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: The EIROS Study [J].

Bengherbia, Monia ;

Berger, Marc ;

Hivert, Benedicte ;

Rigaudier, Florian ;

Bracoud, Luc ;

Vaeterlein, Ole ;

Yousfi, Karima ;

Maric, Michele ;

Malcles, Marie ;

Belmatoug, Nadia .

JOURNAL OF CLINICAL MEDICINE, 2024, 13 (10)

[25] EFFICACY OF ENZYME REPLACEMENT THERAPY WITH VELAGLUCERASE ALFA IN PATIENTS WITH TYPE 1 GAUCHER DISEASE AND THROMBOCYTOPENIA OR SEVERE SPLENOMEGALY [J].

Giraldo, P. ;

Gonzalez, D. ;

Kabra, M. ;

Lukina, E. ;

Kisinovsky, I. ;

Elstein, D. ;

Zahrieh, D. ;

Crombez, E. ;

Zimran, A. .

HAEMATOLOGICA, 2013, 98 :196-197

[26] Combination therapy (eliglustat plus velaglucerase alfa) in a pediatric patient with Gaucher disease type 1 and hereditary spherocytosis [J].

Bailey, Laurie ;

Ambruso, Daniel ;

Grabowski, Gregory ;

Burrow, Thomas A. .

MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) :S17-S17

[27] Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease [J].

Elstein, Deborah ;

Mehta, Atul ;

Hughes, Derralynn A. ;

Giraldo, Pilar ;

Charrow, Joel ;

Smith, Laurie ;

Shankar, Suma P. ;

Hangartner, Thomas N. ;

Kunes, Yune ;

Wang, Nan ;

Crombez, Eric ;

Zimran, Ari .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (07) :592-597

[28] IMPACT OF VELAGLUCERASE ALFA ON QUALITY OF LIFE OF ADULT PATIENTS WITH TYPE-I GAUCHER DISEASE [J].

Elstein, D. ;

Enciu, C. A. ;

Fontaine, L. ;

Piwko, C. .

VALUE IN HEALTH, 2013, 16 (03) :A108-A108

[29] Clinical characteristics of type III Gaucher disease in children and adolescents enrolled in a trial of velaglucerase alfa [J].

Ben Dridi, Marie-Francoise ;

EI-Beshlawy, Amal ;

Marzouk, Iman ;

Bavdekar, Ashish ;

Chang, Peter ;

Mellgard, Bjoern ;

Tantawy, Azza A. G. .

MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) :S21-S21

[30] Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial [J].

Pleat, Rebecca ;

Cox, Timothy M. ;

Burrow, T. Andrew ;

Giraldo, Pilar ;

Goker-Alpan, Ozlem ;

Rosenbloom, Barry E. ;

Croal, Laura R. ;

Underhill, Lisa H. ;

Gaemers, Sebastiaan J. M. ;

Peterschmitt, M. Judith .

MOLECULAR GENETICS AND METABOLISM REPORTS, 2016, 9 :25-28

← 1 2 3 4 5 →